OsI_12825 Antibody

What is the OsI_12825 antibody and what does it target?

OsI_12825 antibody is a polyclonal antibody that targets the Probable E3 ubiquitin-protein ligase BAH1-like 1 (EC 2.3.2.27) in Oryza sativa subsp. indica (Rice). This RING-type E3 ubiquitin transferase plays a role in protein ubiquitination pathways within rice plants . The antibody is typically generated in rabbit hosts and purified through antigen-affinity methods to ensure specific binding to the target protein.

What are the available formats and recommended applications for OsI_12825 antibody?

OsI_12825 antibody is available as a polyclonal antibody preparation, typically in 0.1ml and 10mg quantities (catalog number CSB-PA384881XA01OFF) . The primary recommended applications include ELISA (EIA) and Western Blot (WB) for identification of the target antigen . While not explicitly mentioned in the search results for this specific antibody, typical polyclonal antibodies against plant proteins may also be suitable for immunohistochemistry applications after proper validation.

How should I design proper controls when using OsI_12825 antibody in Western blot applications?

When designing Western blot experiments with OsI_12825 antibody, it's essential to incorporate both positive and negative controls to validate specificity and performance. For positive controls, consider:

• Purified recombinant OsI_12825 protein or overexpression lysates

• Known rice tissue samples with confirmed expression of the target

For negative controls, implement:

• Tissue samples from rice varieties with confirmed lack of expression or knockout mutants

• Pre-absorption controls using the immunizing peptide

• Secondary antibody-only controls to check for non-specific binding

Every experiment should include samples with variable expression levels of the target protein to assess the antibody's dynamic range and specificity .

What are the recommended protein extraction methods to preserve epitope integrity when studying E3 ubiquitin ligases like OsI_12825?

When extracting proteins for OsI_12825 antibody applications, consider that E3 ubiquitin ligases often exist in protein complexes that can be sensitive to extraction conditions. A recommended approach includes:

• Use a buffer containing:

  • 50mM Tris-HCl (pH 7.5)

  • 150mM NaCl

  • 1% Triton X-100 or NP-40

  • 5mM EDTA

  • 1mM DTT

  • Protease inhibitor cocktail

  • Deubiquitinase inhibitors (e.g., N-ethylmaleimide)

• Maintain cold temperatures (4°C) throughout extraction

• Consider crosslinking approaches for capturing transient interactions

• Include phosphatase inhibitors if studying phosphorylation-dependent ubiquitination

This approach helps preserve protein interactions and post-translational modifications that may affect antibody recognition.

What validation approaches should I use to confirm the specificity of OsI_12825 antibody?

Comprehensive validation of OsI_12825 antibody should employ multiple orthogonal methods :

• Genetic Approaches:

  • Compare wild-type rice tissue with OsI_12825 knockdown/knockout lines

  • Use CRISPR-Cas9 edited cell lines lacking the target gene

• Molecular Approaches:

  • Perform immunoprecipitation followed by mass spectrometry

  • Conduct epitope mapping to confirm binding site specificity

  • Run Western blots to confirm molecular weight (look for a single band at the predicted size)

• Independent Antibody Validation:

  • Compare results with a second antibody targeting a different epitope on the same protein

  • Correlate protein detection with mRNA expression data

• Recombinant Expression:

  • Test against recombinant OsI_12825 protein and related E3 ligase family members to assess cross-reactivity

Document all validation steps methodically for publication and reproducibility purposes.

How can I address potential cross-reactivity with other RING-type E3 ubiquitin ligases in rice?

Cross-reactivity is a significant concern when working with antibodies against members of protein families with high sequence similarity, such as RING-type E3 ubiquitin ligases. To address this:

• Sequence Analysis:

  • Perform sequence alignment of OsI_12825 with other RING-type E3 ligases

  • Identify regions of high similarity that might lead to cross-reactivity

• Competitive Binding Assays:

  • Pre-incubate the antibody with recombinant proteins of related family members

  • Observe if this reduces binding to the target protein

• Parallel Testing:

  • Test the antibody against recombinant proteins of related family members (e.g., BAH1-like 2)

  • Run side-by-side Western blots with samples known to express different E3 ligases

• Domain-Specific Analysis:

  • Determine if the antibody epitope corresponds to conserved RING domains or unique regions

  • Consider using domain-specific blocking peptides for competitive assays

• Mass Spectrometry Validation:

  • Perform immunoprecipitation followed by mass spectrometry to identify all captured proteins

Document any cross-reactivity discovered for accurate interpretation of experimental results.

What are the most common causes of inconsistent Western blot results with OsI_12825 antibody and how can they be addressed?

Inconsistency in Western blot results can stem from multiple factors. For OsI_12825 antibody, consider:

• Protein Degradation Issues:

  • E3 ligases often have rapid turnover rates

  • Solution: Add proteasome inhibitors (MG132) during extraction

  • Include higher concentrations of protease inhibitors

• Post-translational Modifications:

  • Ubiquitination, phosphorylation, or SUMOylation may affect epitope recognition

  • Solution: Test different extraction and denaturation conditions

  • Consider phosphatase treatment to remove modifications

• Batch-to-Batch Variability:

  • Polyclonal antibodies inherently have batch variations

  • Solution: Order sufficient quantity from a single lot for long-term studies

  • Consider transitioning to recombinant antibodies for better consistency

• Buffer Incompatibility:

  • Presence of certain detergents may affect epitope accessibility

  • Solution: Test alternative membrane blocking agents and detergents

  • Optimize incubation times and temperatures

• Protein Transfer Issues:

  • Large proteins may transfer inefficiently

  • Solution: Test extended transfer times or alternative transfer methods

  • Consider using gradient gels for better resolution

Document all optimization steps to establish a reliable protocol for future experiments.

How should I interpret and troubleshoot multiple bands when using OsI_12825 antibody in Western blots?

The appearance of multiple bands requires systematic investigation:

• Expected Modifications:

  • E3 ubiquitin ligases often exist in multiple forms due to self-ubiquitination

  • Higher molecular weight bands may represent ubiquitinated forms

  • Lower molecular weight bands could be degradation products or splice variants

• Validation Approach:

  • Compare band patterns across different tissues with varying expression levels

  • Treat samples with deubiquitinating enzymes to remove ubiquitin chains

  • Perform RNA interference to confirm which bands are specific to OsI_12825

• Technical Resolution:

  • Optimize sample preparation (fresher samples, different lysis buffers)

  • Adjust primary antibody concentration (try a dilution series)

  • Modify washing conditions and blocking agents

  • Test different membrane types (PVDF vs. nitrocellulose)

• Documentation Requirements:

  • Always show full blots in publications

  • Document which band corresponds to the target protein

  • Provide molecular weight markers for reference

Multiple bands may represent biologically relevant forms rather than non-specific binding, so careful interpretation is necessary.

How can OsI_12825 antibody be used to study protein-protein interactions within the ubiquitination pathway?

OsI_12825 antibody can be leveraged to investigate protein-protein interactions through several advanced approaches:

• Co-Immunoprecipitation (Co-IP):

  • Use the antibody to pull down OsI_12825 and identify interacting partners

  • Combine with mass spectrometry for unbiased interaction mapping

  • Include crosslinking for capturing transient interactions

• Proximity Labeling:

  • Create fusion proteins with BioID or APEX2 to identify proteins in proximity

  • Use the antibody to confirm expression and localization of the fusion protein

• Immunofluorescence Microscopy:

  • Perform co-localization studies with potential interacting proteins

  • Analyze temporal dynamics of interactions during stress responses

• In vitro Ubiquitination Assays:

  • Immunodeplete OsI_12825 from cell extracts to assess effects on ubiquitination

  • Perform reconstitution experiments with purified components

• Chromatin Immunoprecipitation (ChIP):

  • If nuclear localization is suspected, use the antibody to study chromatin association

  • Combine with sequencing (ChIP-seq) to identify genome-wide binding sites

These approaches can provide comprehensive insights into the functional roles of OsI_12825 in plant stress responses and developmental processes.

How can I adapt techniques from mammalian antibody research to improve plant antibody applications?

Adapting advanced techniques from mammalian antibody research could enhance plant antibody applications:

• Single-Cell Antibody Technologies:

  • Modify protocols from single-cell B cell receptor sequencing studies to analyze plant protein expression at the single cell level

  • Adapt sorting protocols to isolate plant protoplasts for antibody-based detection

• Deep Learning Applications:

  • Utilize algorithms similar to those used for antibody specificity prediction to predict cross-reactivity with related plant proteins

  • Apply computational approaches to identify potential epitopes for improved antibody design

• Biobetter Development:

  • Apply principles from biobetter antibody development to enhance antibody stability under plant extraction conditions

  • Consider modifications to improve antibody performance in plant tissue environments with high polyphenol or polysaccharide content

• Antibody Fragment Technologies:

  • Explore nanobody or single-chain variable fragment (scFv) approaches for better tissue penetration

  • Develop plant-expressed antibody fragments for in vivo studies

• Multi-Omics Integration:

  • Combine antibody-based protein detection with transcriptomics and metabolomics for comprehensive pathway analysis

  • Create databases similar to Observed Antibody Space (OAS) specifically for plant antibody validation

Implementing these advanced techniques would require careful optimization for plant-specific challenges but could significantly advance the field.

How can I integrate OsI_12825 antibody data with other -omics approaches to understand E3 ligase function?

Integrating antibody-based data with other -omics approaches provides comprehensive insights:

• Multi-Omics Framework:

  Approach	Technique	Integration with Antibody Data
  Transcriptomics	RNA-seq	Correlate protein levels with transcript levels
  Proteomics	MS/MS	Validate antibody specificity; identify PTMs
  Ubiquitinomics	Ub-remnant profiling	Map substrates of OsI_12825
  Interactomics	IP-MS, Y2H	Validate antibody-identified interactions
  Metabolomics	LC-MS	Connect E3 ligase activity to metabolic outcomes

• Temporal Analysis:

  • Use the antibody to track protein expression across developmental stages

  • Correlate with stage-specific transcriptome and proteome changes

• Stress Response Integration:

  • Compare OsI_12825 expression under various stresses (drought, salt, pathogens)

  • Connect to global stress response networks through pathway analysis

• Subcellular Localization:

  • Use the antibody for immunolocalization studies

  • Correlate with organelle proteome datasets

• System-Level Modeling:

  • Incorporate antibody-derived protein quantification into mathematical models

  • Predict network behaviors based on E3 ligase activity levels

This integrated approach enables understanding of OsI_12825 function within the broader cellular context.

How do results from OsI_12825 antibody studies compare with data from other RING-type E3 ligases in plants?

Comparative analysis provides important context for interpreting OsI_12825 data:

• Structural and Functional Comparison:

  • Compare immunoblot patterns with other BAH1-like proteins (e.g., BAH1-like 2)

  • Assess differences in subcellular localization, tissue expression, and stress responsiveness

• Evolutionary Context:

  • Compare expression patterns across rice subspecies (indica vs. japonica)

  • Analyze conservation of epitope regions across plant species

• Substrate Specificity:

  • Use immunoprecipitation to identify unique and overlapping substrates

  • Compare ubiquitination patterns through tandem ubiquitin binding entity (TUBE) assays

• Comprehensive Analysis Framework:

  Feature	OsI_12825 (BAH1-like 1)	BAH1-like 2	Other RING E3 Ligases
  MW	[Expected MW based on sequence]	[Comparative MW]	[Range of MWs]
  Expression Pattern	[Tissue specificity]	[Comparative pattern]	[Common patterns]
  Stress Response	[Specific stresses]	[Comparative response]	[General trends]
  Subcellular Localization	[Observed localization]	[Comparative localization]	[Common locations]
  Post-translational Modifications	[Observed PTMs]	[Comparative PTMs]	[Common PTMs]

• Method-Specific Considerations:

  • Compare antibody performance metrics across different E3 ligase family members

  • Identify common technical challenges and solutions

This comparative approach helps place OsI_12825 research in the broader context of plant E3 ligase biology.

How might new antibody technologies improve research on plant E3 ubiquitin ligases?

Emerging antibody technologies could transform plant E3 ligase research:

• Recombinant Antibody Development:

  • Generation of recombinant anti-OsI_12825 antibodies for improved batch consistency

  • Development of high-specificity antibodies using yeast display technology similar to approaches used for therapeutic antibodies

• AI-Designed Antibodies:

  • Application of generative AI approaches used in therapeutic antibody design for plant research

  • Custom antibody design targeting conserved functional domains across E3 ligase families

• Proximity Labeling Antibodies:

  • Integration of antibodies with enzymatic tags for in situ proximity labeling

  • Development of split-BioID or split-APEX systems for detecting protein interactions

• Single-Domain Antibodies:

  • Development of nanobodies against plant E3 ligases inspired by llama antibody research

  • Engineering plant-expressed intrabodies for in vivo modulation of E3 ligase function

• Spatiotemporal Biosensors:

  • Creation of conformation-sensitive antibodies that detect active vs. inactive E3 ligases

  • Development of FRET-based sensors incorporating antibody fragments

These advanced technologies could overcome current limitations in studying dynamic E3 ligase complexes in plants.

What considerations should guide the development of next-generation antibodies for plant ubiquitination research?

Future antibody development for plant ubiquitination research should address:

• Epitope Selection Strategies:

  • Target unique regions rather than conserved RING domains to minimize cross-reactivity

  • Develop antibodies against specific post-translational modifications (phosphorylated or auto-ubiquitinated forms)

  • Create conformation-specific antibodies that distinguish active from inactive states

• Validation Requirements:

  • Implement comprehensive validation standards similar to those proposed for mammalian systems

  • Develop plant-specific validation pipelines accounting for unique challenges

  • Create community databases for antibody validation data sharing

• Technical Specifications:

  • Design antibodies stable under plant extraction conditions (resistant to proteases, polyphenols)

  • Optimize for compatibility with common plant research techniques

  • Develop format variations for diverse applications (visualization, purification, modulation)

• System-Wide Approaches:

  • Generate antibody panels covering entire E3 ligase families

  • Develop multiplexed detection methods for simultaneous analysis of multiple ligases

  • Create standardized antibody arrays for high-throughput phenotyping

• Knowledge Integration:

  • Connect antibody development to emerging plant ubiquitinome databases

  • Apply lessons from large-scale antibody studies like CoV-AbDab and SARS-CoV-2 antibody surveys